Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma

Hyebin Park, Donglu Zhao, George Tsourdinis, Zhishuo Ou, MD, Archito T. Tamayo, MS, Richard J. Ford, MD PhD, Bingliang Fang, MD PhD, Lan V Pham, PhD, Liang Zhang, MD PhD, Michael Wang, MD

Blood (2014) 124 (21): 3028.

https://doi.org/10.1182/blood.V124.21.3028.3028

Published: 2014

Journal Articles

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

Erin M Dominici, Elyse R Lopez, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Christopher J. Kirk, Ph.D

Blood (2013) 122 (21): 1834.

https://doi.org/10.1182/blood.V122.21.1834.1834

Published: 2013

Journal Articles

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL

Lan V Pham, PhD, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Erin M Dominici, Elyse R Lopez, James Pham, Jack Wang, Lauren M Strickland, Michael Wang, MD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 1274.

https://doi.org/10.1182/blood.V122.21.1274.1274

Published: 2013

Journal Articles

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Elyse R Lopez, Erin M Dominici, Muychi T Vang, Archito T. Tamayo, MS, Zhishuo Ou, MD, Alex Rollo, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Christopher J. Kirk, Ph.D, Michael Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Michael Wang, MD, Lan V Pham, PhD, Richard J. Ford, MD, PhD

Blood (2013) 122 (21): 5147.

https://doi.org/10.1182/blood.V122.21.5147.5147

Published: 2013

Journal Articles

Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma

Liang Zhang, MD, PhD, Zhishuo Ou, MD, Jack Wang, Erin M Dominici, Hui Zhang, Richard J. Ford, Jr., MD, PhD, Michael Wang, MD, Lan V Pham, PhD

Blood (2013) 122 (21): 3074.

https://doi.org/10.1182/blood.V122.21.3074.3074

Published: 2013

Journal Articles

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma

Zhishuo Ou, MD, Lan V Pham, PhD, Muychi T Vang, Liang Zhang, MD, PhD, Jack Wang, Lauren M Strickland, Elyse R Lopez, Erin M Dominici, Alex Rollo, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2013) 122 (21): 3079.

https://doi.org/10.1182/blood.V122.21.3079.3079

Published: 2013

Journal Articles

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

L. Kyle Brett, MD, Mark Axelrod, PhD, Zhishuo Ou, MD, Liang Zhang, MD, PhD, Vicki Gordon, BS, Elyse R Lopez, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Michael J. Weber, PhD, Michael E. Williams, MD, ScM, Michael Wang, MD

Blood (2013) 122 (21): 3080.

https://doi.org/10.1182/blood.V122.21.3080.3080

Published: 2013

Journal Articles

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Kejie Zhang, MD, PhD, Lan V Pham, PhD, Liang Zhang, MD, PhD, Archito T. Tamayo, MS, Zhishuo Ou, MD, Dilara McCauley, PhD, Sharon Shacham, PhD, Michael Kauffman, MD, PhD, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 2734.

https://doi.org/10.1182/blood.V118.21.2734.2734

Published: 2011

Journal Articles

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Liang Zhang, MD, PhD, Jianfei Qian, PhD, Zhishuo Ou, MD, Luhong Sun, MD, PhD, Kejie Zhang, MD, PhD, Lan V Pham, PhD, Christopher J Kirk, PhD, Richard J. Ford, MD, PhD, Qing Yi, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 3740.

https://doi.org/10.1182/blood.V118.21.3740.3740

Published: 2011

Journal Articles

Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma

Zhishuo Ou, MD, Lan V Pham, PhD, Liang Zhang, MD, PhD, Archito T. Tamayo, MS, John Lee, MD, Kejie Zhang, MD, PhD, Jacqueline Wang, James Phan, Changping Li, MD, Luhong Sun, MD, PhD, Richard J. Ford, MD, PhD, Michael Wang, MD

Blood (2011) 118 (21): 4971.

https://doi.org/10.1182/blood.V118.21.4971.4971

Published: 2011

NARROW

STAT3 Activation Is Preceded By Two Independent Pathways (BCR-BTK and IL6-JAK) in Mantle Cell Lymphoma

Carfilzomib, a Second-Generation Proteasome Inhibitor, In Combination With The Btk Inhibitor Ibrutinib As a Novel Therapeutic Regimen For Treating Double Hit DLBCL

The Role Of Mir-155 In Controlling Key Growth and Survival Pathways In ABC-Subtype DLBCL

Selective Inhibitor Of Nuclear Exports (SINE) KPT-330 In Combination With The Novel Proteasome Inhibitor Carfilzomib As a Novel Therapeutic Regimen For Treating Aggressive B-Cell Lymphomas

Ibrutinib Overcomes Carfilzomib Resistance In Immunoproteasome-Deficient Mantle Cell Lymphoma

Targeting BCR Activated STAT3 By Ibrutinib In Mantle Cell Lymphoma

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

Novel CRM-1 Inhibitors for Therapy In Mantle Cell Lymphoma

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Single-Agent Bruton's Tyrosine Kinase (Btk) Inhibitor and Single-Agent Carfilzomib Induce Cell Apoptosis, Arrest Cell Growth and Downregulate NF-Kb Activity In Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only